Humoral response after the booster dose of anti-SARS-CoV-2 vaccine in multiple sclerosis patients treated with high-efficacy therapies

Alessandro Maglione; Marta Morra; Raffaella Meroni; Manuela Matta; Marinella Clerico; Simona Rolla

doi:10.1016/j.msard.2022.103776

Humoral response after the booster dose of anti-SARS-CoV-2 vaccine in multiple sclerosis patients treated with high-efficacy therapies

Mult Scler Relat Disord. 2022 May:61:103776. doi: 10.1016/j.msard.2022.103776. Epub 2022 Mar 26.

Authors

Alessandro Maglione¹, Marta Morra¹, Raffaella Meroni¹, Manuela Matta¹, Marinella Clerico², Simona Rolla¹

Affiliations

¹ Department of Clinical and Biological Sciences, University of Turin, Italy.
² Department of Clinical and Biological Sciences, University of Turin, Italy. Electronic address: marinella.clerico@unito.it.

Abstract

Anti-SARS-CoV2 mRNA vaccines showed a blunted antibody (Ab) response in people with MS (pwMS) on high efficacy therapies, suggesting the need for a booster dose. We evaluated the kinetics of the production of anti-receptor binding domain (RBD) Immunoglobulins G (IgG) after the vaccination cycle and the booster in pwMS receiving ocrelizumab, fingolimod and cladribine. A significant increase of anti-RBD IgG seroconversion was observed after booster respect to the vaccination cycle. Results obtained from this study will be useful for the management of pwMS in relation to their disease modifying therapy (DMT) and for any future vaccination campaign.

Keywords: Anti-SARS-Cov2 vaccine; Booster; Multiple sclerosis; Third dose.

Publication types

Letter

MeSH terms

Antibodies, Viral
COVID-19 Vaccines
COVID-19* / prevention & control
Humans
Immunoglobulin G / therapeutic use
Multiple Sclerosis* / drug therapy
SARS-CoV-2

Substances

Antibodies, Viral
COVID-19 Vaccines
Immunoglobulin G